Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.51 |
| ▸ | AR | P10275 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11783518 | 0.87 | AR (0.57) | SLC22A12ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL28697603 | 0.86 | SLC22A12 (0.51) | SLC22A12ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL11756420 | 0.86 | SLC22A12 (0.53) | SLC22A12ARHTR2ASLC6A4 | |
| SCHEMBL13295195 | 0.81 | PDE7A (0.49) | KDM4EALDH1A1PDE7AHTR2ASLC6A4 | |
| SCHEMBL28288101 | 0.78 | HTR2A (0.55) | SLC22A12ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL28677206 | 0.78 | KDM4E (0.53) | SLC22A12ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL11424391 | 0.78 | MERTK (0.49) | ARKDM4EUSP2ALDH1A1PDE7A | |
| SCHEMBL10535321 | 0.77 | TRPV4 (0.55) | SLC22A12AR | |
| SCHEMBL3426930 | 0.75 | HTR2A (0.49) | KDM4EALDH1A1PDE7AHTR2ASLC6A4 | |
| SCHEMBL28677203 | 0.75 | AR (0.53) | SLC22A12ARKDM4EUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2006-10-26 | — | — | US | disclosed |
| EP-1562935-B1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | ROCK1, ROCK2, RHOA | SLC22A12 4566/4885AR 4578/4885KDM4E 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.